Skip to search formSkip to main contentSkip to account menu

PRT064445

National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Factor XaRecombinant Proteins

Narrower (2)

andexanetandexanet alfa

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
A Systematic and Evidence-Based Review of Published and Pending Reports of Andexanet Alfa
Andexanet alfa is the newly approved factor Xa inhibitor reversal agent for the treatment of life-threatening or uncontrolled… 
Review
2016
Review
2016
Classes of Drugs and Blood Products for Acute Reversal of Anticoagulant Effect
The reversal of anticoagulation in a timely and safe manner is crucial to the effective management of an anticoagulated patient… 
2014
2014
reversal of enoxaparin-induced anticoagulation in healthy subjects by andexanet alfa (prt064445), an antidote for direct and indirect fxa inhibitors—a phase 2 randomized, double-blind, placebo…
2013
2013
PRT064445 reverses rivaroxaban induced anticoagulation in a rabbit liver laceration treatment model
We previously demonstrated in a rabbit liver laceration model that prophylactic administration of PRT064445 (PRT), a recombinant… 
2013
2013
Antidotes edge closer to reversing effects of new blood thinners
The US approval late last year of the blood thinner Eliquis (apixaban) made it the third blood-thinner pill option to come online… 
2012
2012
PRT064445 but Not Recombinant Fviia Reverses Rivaroxaban Induced Anticoagulation As Measured by Reduction in Blood Loss in a Rabbit Liver Laceration Model
Abstract 3414 We used a modified rabbit liver laceration model to demonstrate the effects of PRT064445, a recombinant fXa… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)